RU2214247C2 - Применение производных рапамицина при вазопатиях и ксенотрансплантации - Google Patents

Применение производных рапамицина при вазопатиях и ксенотрансплантации Download PDF

Info

Publication number
RU2214247C2
RU2214247C2 RU98119312/14A RU98119312A RU2214247C2 RU 2214247 C2 RU2214247 C2 RU 2214247C2 RU 98119312/14 A RU98119312/14 A RU 98119312/14A RU 98119312 A RU98119312 A RU 98119312A RU 2214247 C2 RU2214247 C2 RU 2214247C2
Authority
RU
Russia
Prior art keywords
rapamycin
recipient
monoclonal antibodies
hydroxyethyl
organ
Prior art date
Application number
RU98119312/14A
Other languages
English (en)
Russian (ru)
Other versions
RU98119312A (ru
Inventor
Вальтер Шулер
Хендрик ШУУРМАН
Гизберт ВЕКБЕККЕР
Ханс-Гюнтер ЦЕРВЕС
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10791127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2214247(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU98119312A publication Critical patent/RU98119312A/ru
Application granted granted Critical
Publication of RU2214247C2 publication Critical patent/RU2214247C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU98119312/14A 1996-03-27 1997-03-26 Применение производных рапамицина при вазопатиях и ксенотрансплантации RU2214247C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9606452.2 1996-03-27
GBGB9606452.2A GB9606452D0 (en) 1996-03-27 1996-03-27 Organic compounds

Publications (2)

Publication Number Publication Date
RU98119312A RU98119312A (ru) 2000-09-10
RU2214247C2 true RU2214247C2 (ru) 2003-10-20

Family

ID=10791127

Family Applications (1)

Application Number Title Priority Date Filing Date
RU98119312/14A RU2214247C2 (ru) 1996-03-27 1997-03-26 Применение производных рапамицина при вазопатиях и ксенотрансплантации

Country Status (29)

Country Link
US (5) US6384046B1 (cg-RX-API-DMAC10.html)
EP (3) EP0893996B1 (cg-RX-API-DMAC10.html)
JP (2) JP2000507226A (cg-RX-API-DMAC10.html)
KR (2) KR100836971B1 (cg-RX-API-DMAC10.html)
CN (1) CN1124135C (cg-RX-API-DMAC10.html)
AT (1) ATE224194T1 (cg-RX-API-DMAC10.html)
AU (1) AU716514B2 (cg-RX-API-DMAC10.html)
BR (1) BR9708358A (cg-RX-API-DMAC10.html)
CA (1) CA2247275C (cg-RX-API-DMAC10.html)
CY (1) CY2404B1 (cg-RX-API-DMAC10.html)
CZ (1) CZ292483B6 (cg-RX-API-DMAC10.html)
DE (1) DE69715611T2 (cg-RX-API-DMAC10.html)
DK (2) DK0893996T3 (cg-RX-API-DMAC10.html)
ES (2) ES2184078T3 (cg-RX-API-DMAC10.html)
GB (1) GB9606452D0 (cg-RX-API-DMAC10.html)
HU (1) HU226422B1 (cg-RX-API-DMAC10.html)
ID (1) ID17195A (cg-RX-API-DMAC10.html)
IL (1) IL125812A (cg-RX-API-DMAC10.html)
MY (1) MY117798A (cg-RX-API-DMAC10.html)
NO (1) NO316667B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ331463A (cg-RX-API-DMAC10.html)
PL (1) PL187732B1 (cg-RX-API-DMAC10.html)
PT (2) PT2008657E (cg-RX-API-DMAC10.html)
RU (1) RU2214247C2 (cg-RX-API-DMAC10.html)
SI (1) SI2008657T1 (cg-RX-API-DMAC10.html)
SK (1) SK284343B6 (cg-RX-API-DMAC10.html)
TR (1) TR199801919T2 (cg-RX-API-DMAC10.html)
WO (1) WO1997035575A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA972719B (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012158130A1 (en) 2011-05-18 2012-11-22 Co Ltd. "Mabela" Substance enhancing biocompatibility of implants with recipient body and method of its preparation.

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
DE69736750T2 (de) 1996-07-30 2007-08-16 Novartis Ag Pharmazeutische zusammensetzungen zur behandlung der transplantatabstossung sowie der autoimmun- oder entzündlichen zustände
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US20030129215A1 (en) * 1998-09-24 2003-07-10 T-Ram, Inc. Medical devices containing rapamycin analogs
WO2000067773A2 (en) * 1999-05-10 2000-11-16 Novartis Ag Combinations of immunosupressive agents for the treatment or prevention of graft rejections
US7807211B2 (en) 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US20070032853A1 (en) * 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US6790228B2 (en) 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US20070055367A1 (en) * 2000-03-15 2007-03-08 Orbus Medical Technologies, Inc. Medical device with coating that promotes endothelial cell adherence and differentiation
US8460367B2 (en) * 2000-03-15 2013-06-11 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
WO2001068158A1 (en) 2000-03-15 2001-09-20 Orbus Medical Technologies Inc. Coating that promotes endothelial cell adherence
US20030229393A1 (en) * 2001-03-15 2003-12-11 Kutryk Michael J. B. Medical device with coating that promotes cell adherence and differentiation
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US20070141107A1 (en) * 2000-03-15 2007-06-21 Orbusneich Medical, Inc. Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
US20050002986A1 (en) * 2000-05-12 2005-01-06 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
US7300662B2 (en) 2000-05-12 2007-11-27 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US20020013335A1 (en) * 2000-06-16 2002-01-31 American Home Products Corporation Method of treating cardiovascular disease
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
EP1709974A3 (en) * 2000-06-16 2006-12-06 Wyeth Method of treating cardiovascular disease using rapamycin
WO2002026139A1 (en) 2000-09-29 2002-04-04 Cordis Corporation Coated medical devices
CN1551767A (zh) * 2001-02-19 2004-12-01 ��˹��ŵ�� 癌症的治疗
US8741378B1 (en) 2001-06-27 2014-06-03 Advanced Cardiovascular Systems, Inc. Methods of coating an implantable device
US6939376B2 (en) 2001-11-05 2005-09-06 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US7682387B2 (en) 2002-04-24 2010-03-23 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
WO2003070275A1 (en) * 2002-02-22 2003-08-28 Prophy Med Ab Use of an inhibitor or antagonist against tissue factor
US20040024450A1 (en) * 2002-04-24 2004-02-05 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
CN1655738A (zh) * 2002-05-20 2005-08-17 奥勃斯医学技术股份有限公司 可植入的药物洗脱医疗装置
US8109987B2 (en) 2003-04-14 2012-02-07 Tryton Medical, Inc. Method of treating a lumenal bifurcation
US7279174B2 (en) 2003-05-08 2007-10-09 Advanced Cardiovascular Systems, Inc. Stent coatings comprising hydrophilic additives
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US7220755B2 (en) 2003-11-12 2007-05-22 Biosensors International Group, Ltd. 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
US9114198B2 (en) 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
WO2005107817A2 (en) * 2004-04-30 2005-11-17 Orbus Medical Technologies, Inc. Medical device with coating for capturing genetically-altered cells and methods of using same
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
US8709469B2 (en) 2004-06-30 2014-04-29 Abbott Cardiovascular Systems Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US7901451B2 (en) 2004-09-24 2011-03-08 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US20060194829A1 (en) * 2004-12-20 2006-08-31 Clackson Timothy P Therapeutic materials and methods
AU2006315512B2 (en) 2005-11-14 2012-11-01 Ariad Pharmaceuticals, Inc. Administration of an mTOR inhibitor to treat patients with cancer
CN101340859B (zh) * 2005-11-17 2010-12-15 路嘉株式会社 用于制备在对身体的医疗手术中使用的插入物的方法
US20070173923A1 (en) * 2006-01-20 2007-07-26 Savage Douglas R Drug reservoir stent
US7867988B2 (en) 2006-09-13 2011-01-11 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US20080097591A1 (en) 2006-10-20 2008-04-24 Biosensors International Group Drug-delivery endovascular stent and method of use
US8067055B2 (en) * 2006-10-20 2011-11-29 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method of use
US20080103584A1 (en) * 2006-10-25 2008-05-01 Biosensors International Group Temporal Intraluminal Stent, Methods of Making and Using
KR100930167B1 (ko) * 2007-09-19 2009-12-07 삼성전기주식회사 초광각 광학계
US8661630B2 (en) 2008-05-21 2014-03-04 Abbott Cardiovascular Systems Inc. Coating comprising an amorphous primer layer and a semi-crystalline reservoir layer
CA2705764C (en) 2007-11-14 2016-08-02 Biosensors International Group, Ltd. Automated stent coating apparatus and method
EP2245165A4 (en) * 2008-01-11 2011-06-01 Massachusetts Eye & Ear Infirm TRANSGENIC CONDITIONAL STOP DIMERICABLE CASPASE ANIMALS
EP2352459A4 (en) * 2008-10-03 2013-09-25 Elixir Medical Corp MACROCYCLIC LACTON COMPOUNDS AND METHOD FOR THEIR USE
US8366763B2 (en) 2009-07-02 2013-02-05 Tryton Medical, Inc. Ostium support for treating vascular bifurcations
US8685433B2 (en) 2010-03-31 2014-04-01 Abbott Cardiovascular Systems Inc. Absorbable coating for implantable device
CN102268015B (zh) * 2011-08-30 2013-08-28 成都摩尔生物医药有限公司 一种依维莫司的合成方法
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
KR101723265B1 (ko) 2013-08-16 2017-04-04 가톨릭대학교 산학협력단 mTOR/STAT3 신호억제제 처리된 면역조절능을 갖는 간엽줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
CA3059017C (en) 2013-09-24 2021-05-25 Giner Life Sciences, Inc. System for gas treatment of a cell implant
CN106061482A (zh) 2013-10-08 2016-10-26 拉姆医疗公司 用于治疗淋巴管平滑肌瘤病的雷帕霉素
RU2016136348A (ru) 2014-02-11 2018-03-16 Лэм Терапьютикс, Инк. Рапамицин для лечения лимфангиолейомиоматоза
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
NZ724756A (en) 2014-04-04 2023-07-28 Ai Therapeutics Inc An inhalable rapamycin formulation for treating age-related conditions
CA2963085C (en) 2014-10-07 2023-02-21 Lam Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
MA40910A (fr) 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
WO2016130645A1 (en) 2015-02-10 2016-08-18 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
US20190167649A1 (en) 2016-08-10 2019-06-06 The Board Of Regents Of The University Of Texas System Topical rapamycin therapy
CN109715224B (zh) 2016-09-19 2022-02-22 百多力股份公司 无聚合物的药物洗脱血管支架
JP6993003B2 (ja) 2016-11-15 2022-01-13 ガイナー ライフ サイエンシズ,インク. 皮下インプラントとの使用に適した経皮的ガス拡散装置
US11826492B2 (en) 2016-12-22 2023-11-28 Biotronik Ag Intratumoral drug delivery materials and methods for treating breast cancer
EP3618916A4 (en) 2017-05-04 2021-04-14 Giner Life Sciences, Inc. ROBUST IMPLANTABLE GAS DISPENSING DEVICE AND PROCEDURES, SYSTEMS AND DEVICES THEREFORE
UY37900A (es) 2017-09-26 2019-04-30 Novartis Ag Nuevos derivados de rapamicina
LT3898637T (lt) 2018-12-18 2025-03-10 Novartis Ag Rapamicino dariniai
AU2020226527A1 (en) 2019-02-20 2021-10-14 AI Therapeutics, Inc. Topical rapamycin formulations and their use in treating facial angiofibromas and other skin disorders
KR20260115158A (ko) 2019-03-26 2026-07-23 노파르티스 아게 이소티아졸리딘 1,1-디옥시드 및 1,4-부탄 술톤 함유 라파마이신 유도체 및 이의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009010A1 (en) * 1992-10-09 1994-04-28 Sandoz Ltd. O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
RU2048812C1 (ru) * 1991-07-25 1995-11-27 Юниверсити оф Луисвилл Рисерч Фаундейшн, Инк. Способ лечения воспалительных заболеваний глаза и средство для лечения воспалительных заболеваний глаза

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
US5364612A (en) * 1991-05-06 1994-11-15 Immunomedics, Inc. Detection of cardiovascular lesions
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
CA2086642C (en) * 1992-01-09 2004-06-15 Randall E. Morris Method of treating hyperproliferative vascular disease
CA2094858C (en) * 1992-04-28 2004-06-15 Robert D. Mitchell Method of treating hyperproliferative vascular disease
US5747034A (en) * 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
US5283257A (en) * 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
BR9408323A (pt) * 1993-12-17 1997-08-19 Sandoz Ag Derivados de rapamicina
US6265427B1 (en) * 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
DE69624921T2 (de) * 1995-06-09 2003-09-11 Novartis Ag, Basel Rapamycinderivate
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2048812C1 (ru) * 1991-07-25 1995-11-27 Юниверсити оф Луисвилл Рисерч Фаундейшн, Инк. Способ лечения воспалительных заболеваний глаза и средство для лечения воспалительных заболеваний глаза
WO1994009010A1 (en) * 1992-10-09 1994-04-28 Sandoz Ltd. O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012158130A1 (en) 2011-05-18 2012-11-22 Co Ltd. "Mabela" Substance enhancing biocompatibility of implants with recipient body and method of its preparation.

Also Published As

Publication number Publication date
DK0893996T3 (da) 2002-12-09
SK284343B6 (sk) 2005-02-04
DK2008657T3 (da) 2013-07-22
NZ331463A (en) 2001-10-26
EP2008657B1 (en) 2013-04-24
EP0893996B1 (en) 2002-09-18
KR20050038656A (ko) 2005-04-27
MY117798A (en) 2004-08-30
PT2008657E (pt) 2013-07-12
CY2404B1 (en) 2004-09-10
IL125812A0 (en) 1999-04-11
HUP0001267A2 (hu) 2000-11-28
WO1997035575A1 (en) 1997-10-02
ID17195A (id) 1997-12-11
HK1018688A1 (en) 1999-12-30
CN1124135C (zh) 2003-10-15
PL187732B1 (pl) 2004-09-30
SI2008657T1 (sl) 2013-07-31
AU716514B2 (en) 2000-02-24
NO316667B1 (no) 2004-03-29
NO984340L (no) 1998-09-18
GB9606452D0 (en) 1996-06-05
JP2000507226A (ja) 2000-06-13
CZ307098A3 (cs) 1999-01-13
US20140187574A1 (en) 2014-07-03
BR9708358A (pt) 1999-08-03
ZA972719B (en) 1998-09-28
EP2008657A3 (en) 2009-02-04
US20120177690A1 (en) 2012-07-12
CA2247275A1 (en) 1997-10-02
US20020127248A1 (en) 2002-09-12
JP5124431B2 (ja) 2013-01-23
ES2421455T3 (es) 2013-09-02
EP1149581A3 (en) 2003-12-03
SK132798A3 (en) 1999-03-12
US6384046B1 (en) 2002-05-07
JP2009102349A (ja) 2009-05-14
EP2008657A2 (en) 2008-12-31
ES2184078T3 (es) 2003-04-01
EP0893996A1 (en) 1999-02-03
US20100152105A1 (en) 2010-06-17
PL328659A1 (en) 1999-02-15
ATE224194T1 (de) 2002-10-15
KR100836971B1 (ko) 2008-06-10
HU226422B1 (en) 2008-12-29
KR20070083654A (ko) 2007-08-24
NO984340D0 (no) 1998-09-18
EP1149581A2 (en) 2001-10-31
DE69715611D1 (de) 2002-10-24
PT893996E (pt) 2002-12-31
HUP0001267A3 (en) 2002-01-28
AU2291897A (en) 1997-10-17
CN1214631A (zh) 1999-04-21
DE69715611T2 (de) 2003-05-22
TR199801919T2 (xx) 1999-02-22
CZ292483B6 (cs) 2003-09-17
CA2247275C (en) 2011-10-11
IL125812A (en) 2001-12-23

Similar Documents

Publication Publication Date Title
JP5124431B2 (ja) 血管疾病および異種移植におけるラパマイシン誘導体の使用
JP2009102349A6 (ja) 血管疾病および異種移植におけるラパマイシン誘導体の使用
RU2217136C2 (ru) Новое применение 1,3-пропандиольных производных
JP7262100B2 (ja) 長期寛容を誘導するためのおよびアテローム性動脈硬化症におけるマクロファージ蓄積を解決するための自然免疫システムの標的化
JP2002544167A (ja) 有機化合物
KR100616020B1 (ko) 맥관장애및이종이식술에서의라파마이신유도체의용도
HK1018688B (en) Use of rapamycin derivatives in vasculopqthies and xenotransplantation
TW550074B (en) Pharmaceutical composition for preventing or treating vasculopathies and chronic rejection